Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00280865 | GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes | PHASE2 | COMPLETED | 500 | — | — | Apr 1, 2002 | Jun 1, 2003 | Jul 31, 2006 | 110 | United States, Canada +2 |
| Name | Type | Description |
|---|---|---|
| Tesaglitazar | DRUG | - |
| Pioglitazone | DRUG | - |
| Dietary and Lifestyle Modification Counseling | BEHAVIORAL | - |
Inclusion Criteria: * Provision of a written informed consent * Men or women who are 30 to 80 years of age * Female patients: postmenopausal or surgically sterile * Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL * Treated with diet alone or treatment with a single oral antidiabet...